Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
Sponsor: Merck Sharp & Dohme LLC
This PHASE2 trial investigates HPV Positive Oropharyngeal Squamous Cell Carcinoma and Metastatic Head and Neck Cancer and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 29 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
29 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 24 earlier versions
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- PDS Biotechnology Corp.
For direct contact, visit the study record on ClinicalTrials.gov .